(Q37016107)

17 August 2017

1 reference

title

An update on the pharmacology of galantamine (English)

1 reference

17 August 2017

1 reference

Manuela G López

4

0 references

Antonio G. García

object named as

Antonio G García

series ordinal

2

0 references

author name string

Mercedes Villarroya

series ordinal

1

1 reference

17 August 2017

José Marco-Contelles

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

16

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1987-1998

1 reference

Genetic neurodegenerative diseases: the human illness and transgenic models

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

The cholinergic hypothesis of geriatric memory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Cholinergic markers in elderly patients with early signs of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

NMDA receptor pathways as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Modulation of N-methyl-D-aspartate receptors by donepezil in rat cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Review of the acetylcholinesterase inhibitor galanthamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Studies on new, centrally active and reversible acetylcholinesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Glutamatergic systems in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Unconventional ligands and modulators of nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Galantamine increases excitability of CA1 hippocampal pyramidal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Mecamylamine interactions with galantamine and donepezil: effects on learning, acetylcholinesterase, and nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Central nicotinic receptors, neurotrophic factors and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Stimulation of nicotinic acetylcholine receptors protects motor neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

AMPA receptor potentiators for the treatment of CNS disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Galantamine-induced behavioral recovery after sublethal excitotoxic lesions to the rat medial septum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

The metabolism and excretion of galantamine in rats, dogs, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Effects of Two-Year Treatment with the Cholinesterase Inhibitor Rivastigmine on Behavioural Symptoms in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

Turning down, but not off.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1987

10.1517/13543784.16.12.1987

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference